XERS Stock Overview
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$2.88 |
| 52 Week Low | US$0.97 |
| Beta | 0 |
| 1 Month Change | 2.40% |
| 3 Month Change | 1.59% |
| 1 Year Change | -54.77% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -45.76% |
Recent News & Updates
Recent updates
Xeris Pharmaceuticals Q2 2022 Earnings Preview
Aug 09Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal
Aug 01Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
May 21Xeris Continues To Execute And Build Long-Term Value Potential
Feb 22Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition
Dec 20Shareholder Returns
| XERS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.2% | -1.3% | -0.3% |
| 1Y | -54.8% | -6.1% | -14.8% |
Return vs Industry: XERS underperformed the US Pharmaceuticals industry which returned -6.1% over the past year.
Return vs Market: XERS underperformed the US Market which returned -14.8% over the past year.
Price Volatility
| XERS volatility | |
|---|---|
| XERS Average Weekly Movement | 12.0% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XERS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: XERS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 355 | Paul Edick | https://www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
| XERS fundamental statistics | |
|---|---|
| Market Cap | US$175.73m |
| Earnings (TTM) | -US$94.66m |
| Revenue (TTM) | US$110.25m |
1.6x
P/S Ratio-1.9x
P/E RatioIs XERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XERS income statement (TTM) | |
|---|---|
| Revenue | US$110.25m |
| Cost of Revenue | US$22.63m |
| Gross Profit | US$87.61m |
| Other Expenses | US$182.27m |
| Earnings | -US$94.66m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 79.47% |
| Net Profit Margin | -85.86% |
| Debt/Equity Ratio | 414.0% |
How did XERS perform over the long term?
See historical performance and comparison